Health
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy – News-Medical.net
Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avacta’s neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future globa…
-
Business18 hours agoBroker names 2 small cap ASX shares to buy for big returns
-
Noosa News24 hours agoQueenslanders not out of the woods as more storms, heatwave conditions to continue after horror three days
-
Business17 hours agoThese top ASX 200 stocks could rise 25% to 60%
-
Noosa News17 hours agoDid AI write your accounting expert’s report? – Proctor